However, due to rapidly emerging resistance to monotherapy based on BRAF inhibitors and the reactivation of the MAPK signaling pathway, the current standard treatment for melanoma is the use of a combined therapy based on, i.e., both MEK and BRAF inhibitors. Here, MAP2K7 is linked to melanoma.